This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks.com featured highlights include: ModivCare, Meridian Corp, Genco Shipping, Capital Product Partners and Costamare
by Zacks Equity Research
Zacks.com featured highlights include: ModivCare, Meridian Corp, Genco Shipping, Capital Product Partners and Costamare
5 Top-Rated Stocks With Solid Net Profit Margins
by Anirudha Bhagat
Here are five top-ranked stocks with solid net profit margins that can contribute toward making a solid portfolio.
MODV vs. AMEH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MODV vs. AMEH: Which Stock Is the Better Value Option?
ModivCare (MODV) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 35.83% and 1.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ModivCare (MODV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ModivCare (MODV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.
MODV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. GDRX: Which Stock Is the Better Value Option?
Avantor, Inc. (AVTR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Acadia Healthcare (ACHC) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Acadia Healthcare (ACHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
by Zacks Equity Research
Zacks Industry Outlook Highlights: HealthEquity, Progyny, Surgery Partners, ModivCare and Agiliti
5 Medical Services Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most. However, falling healthcare spending may disrupt the trend.
MODV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
MODV vs. GDRX: Which Stock Is the Better Value Option?
Here's What Could Help ModivCare (MODV) Maintain Its Recent Price Strength
by Zacks Equity Research
ModivCare (MODV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
MODV or CRL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MODV vs. CRL: Which Stock Is the Better Value Option?
ModivCare (MODV) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 43.92% and 1.43%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ModivCare (MODV) Q2 Earnings Expected to Decline
by Zacks Equity Research
ModivCare (MODV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ModivCare (MODV) Tops Q1 Earnings Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 12.94% and -0.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q1 Earnings Due on May 7: ELAN, MD, MODV
by Sapna Bagaria
Varied companies across the vast healthcare space might have been affected differently by the COVID crisis during the first quarter.
ModivCare (MODV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
ModivCare (MODV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ModivCare (MODV) Surges 5.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
ModivCare (MODV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Establishment Labs (ESTA) Catches Eye: Stock Jumps 5.7%
by Zacks Equity Research
Establishment Labs (ESTA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.